Key points are not available for this paper at this time.
In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment.
Blažek et al. (Thu,) studied this question.